RANI Stock Analysis: Buy, Sell, or Hold?
RANI - Rani Therapeutics Holdings, Inc. Class A Common Stock
$0.75
-0.06 (-7.57%)
▼
5d:
-34.28%
30d:
-45.31%
90d:
-46.48%
WAIT
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
RANI is down 13.1% this week, but smart money is accumulating calls. Top strike: $1.5 2026-04-17 with 1,789 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When RANI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RANI is down 34.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RANI is down 34.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RANI is currently trading at $0.75, which is considered oversold relative to its 30-day fair value range of $1.08 to $1.40.
Technical Outlook: Technically, RANI is in a downtrend. Immediate support is located at $0.70, while resistance sits at $1.36. Short-term momentum is weak, with the stock down 7.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.00 (+886.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RANI is in a downtrend. Immediate support is located at $0.70, while resistance sits at $1.36. Short-term momentum is weak, with the stock down 7.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.00 (+886.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.08 -
$1.40
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.6%)
- BULLISH: Trading 886.9% below Wall St target ($8.00)
- WARNING: Recommendation downgraded due to -34.3% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.08 -
$1.40
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.70
Resistance Level
$1.37
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.56
Wall Street Target
$8.00
(+886.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: March 30, 2026 12:18 PM ET
Data refreshes hourly during market hours. Next update: 1:18 PM
Data refreshes hourly during market hours. Next update: 1:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RANI showing a specific setup today?
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Mir A Imran
BUY
2083334 shares
2025-10-23
South Cone Investments L…
SELL
4000000 shares
2025-10-21
South Cone Investments L…
SELL
1923000 shares
2025-10-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 47 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 51 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
